A Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders
2024

Topiramate for Treating Cannabis Use Disorder in Adolescents with Bipolar Disorder

Sample size: 75 publication 10 minutes Evidence: moderate

Author Information

Author(s): Jenni E. Farrow, Melissa P. DelBello, Luis R. Patino, Thomas J. Blom, Jeffrey A. Welge

Primary Institution: University of Cincinnati College of Medicine

Hypothesis

The study aims to evaluate the efficacy of adjunctive topiramate for the treatment of cannabis use disorder in adolescents with bipolar I disorder.

Conclusion

Topiramate is an effective treatment that reduces cannabis use and weight gain in adolescents with bipolar I disorder.

Supporting Evidence

  • The TPM group showed a significant decrease in cannabis use compared to the placebo group.
  • Participants in the TPM group experienced less weight gain than those in the placebo group.
  • TPM was well-tolerated with manageable side effects.

Takeaway

This study shows that giving topiramate along with other treatments helps young people with bipolar disorder use less cannabis and gain less weight.

Methodology

The study was a 16-week, double-blind, randomized, placebo-controlled trial comparing topiramate plus quetiapine to quetiapine plus placebo.

Potential Biases

Potential bias due to the lack of diversity in the participant demographics.

Limitations

The study had a predominantly White sample, which may limit generalizability, and did not formally assess cognitive changes or ADHD symptoms over time.

Participant Demographics

Participants were adolescents aged 12-21, with a mean age of 17.4 years, predominantly White.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1016/j.jaacop.2024.08.002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication